BioCentury | Sep 12, 2016
Clinical News

TXA709 regulatory update

...expects the S. aureus cell division protein FtsZ inhibitor to enter the clinic in 2Q17. Taxis Pharmaceuticals Inc....
BioCentury | Sep 28, 2015
Clinical News

Taxis Pharmaceuticals preclinical data

...joint meeting in San Diego. TXA709 is an S. aureus cell division protein FtsZ inhibitor. Taxis Pharmaceuticals Inc....
BioCentury | Jun 4, 2015
Translation in Brief

If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by...
Items per page:
1 - 3 of 3
BioCentury | Sep 12, 2016
Clinical News

TXA709 regulatory update

...expects the S. aureus cell division protein FtsZ inhibitor to enter the clinic in 2Q17. Taxis Pharmaceuticals Inc....
BioCentury | Sep 28, 2015
Clinical News

Taxis Pharmaceuticals preclinical data

...joint meeting in San Diego. TXA709 is an S. aureus cell division protein FtsZ inhibitor. Taxis Pharmaceuticals Inc....
BioCentury | Jun 4, 2015
Translation in Brief

If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by...
Items per page:
1 - 3 of 3